vs
Ceribell, Inc.（CBLL）与IRIDEX CORP（IRIX）财务数据对比。点击上方公司名可切换其他公司
Ceribell, Inc.的季度营收约是IRIDEX CORP的1.7倍（$24.8M vs $14.7M）
Ceribell, Inc.是一家专注于神经诊断领域的医疗科技企业，主打便携式快速脑电图检测设备，可为急症、重症护理场景提供便捷的癫痫发作监测解决方案，核心市场覆盖北美地区，目前正逐步推进全球化业务布局。
IRIDEX Corporation是一家全球性医疗科技企业，主要研发、生产和销售面向眼科及医疗美容领域的激光类医疗设备，产品供应至北美、欧洲、亚太等地区的医疗机构与诊所，为眼部疾病治疗和医美项目提供微创解决方案。
CBLL vs IRIX — 直观对比
营收规模更大
CBLL
是对方的1.7倍
$14.7M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $24.8M | $14.7M |
| 净利润 | $-13.5M | — |
| 毛利率 | 87.3% | 37.2% |
| 营业利润率 | -58.9% | — |
| 净利率 | -54.6% | — |
| 营收同比 | — | -69.7% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-0.35 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CBLLIRIX
| Q4 25 | $24.8M | $14.7M | ||
| Q3 25 | $22.6M | $12.5M | ||
| Q2 25 | $21.2M | $13.6M | ||
| Q1 25 | $20.5M | $11.9M | ||
| Q4 24 | — | $12.7M | ||
| Q3 24 | $17.2M | $11.6M | ||
| Q2 24 | — | $12.6M | ||
| Q1 24 | — | $11.8M |
净利润CBLLIRIX
| Q4 25 | $-13.5M | — | ||
| Q3 25 | $-13.5M | $-1.6M | ||
| Q2 25 | $-13.6M | $-994.0K | ||
| Q1 25 | $-12.8M | $-1.7M | ||
| Q4 24 | — | $-834.0K | ||
| Q3 24 | $-10.4M | $-1.9M | ||
| Q2 24 | — | $-2.7M | ||
| Q1 24 | — | $-3.5M |
毛利率CBLLIRIX
| Q4 25 | 87.3% | 37.2% | ||
| Q3 25 | 88.3% | 32.1% | ||
| Q2 25 | 88.1% | 34.5% | ||
| Q1 25 | 87.9% | 42.5% | ||
| Q4 24 | — | 44.0% | ||
| Q3 24 | 87.3% | 37.3% | ||
| Q2 24 | — | 40.7% | ||
| Q1 24 | — | 37.9% |
营业利润率CBLLIRIX
| Q4 25 | -58.9% | — | ||
| Q3 25 | -64.8% | -11.3% | ||
| Q2 25 | -70.5% | -6.9% | ||
| Q1 25 | -69.3% | -1.7% | ||
| Q4 24 | — | -3.9% | ||
| Q3 24 | -57.8% | -16.1% | ||
| Q2 24 | — | -20.9% | ||
| Q1 24 | — | -28.0% |
净利率CBLLIRIX
| Q4 25 | -54.6% | — | ||
| Q3 25 | -59.6% | -12.6% | ||
| Q2 25 | -64.4% | -7.3% | ||
| Q1 25 | -62.4% | -14.2% | ||
| Q4 24 | — | -6.6% | ||
| Q3 24 | -60.6% | -16.7% | ||
| Q2 24 | — | -21.2% | ||
| Q1 24 | — | -29.5% |
每股收益（稀释后）CBLLIRIX
| Q4 25 | $-0.35 | — | ||
| Q3 25 | $-0.37 | $-0.09 | ||
| Q2 25 | $-0.38 | $-0.06 | ||
| Q1 25 | $-0.36 | $-0.10 | ||
| Q4 24 | — | $-0.05 | ||
| Q3 24 | $-1.85 | $-0.12 | ||
| Q2 24 | — | $-0.16 | ||
| Q1 24 | — | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $159.3M | $6.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $155.3M | — |
| 总资产 | $195.8M | $29.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CBLLIRIX
| Q4 25 | $159.3M | $6.0M | ||
| Q3 25 | $168.5M | $5.6M | ||
| Q2 25 | $177.4M | $6.8M | ||
| Q1 25 | $182.7M | $7.2M | ||
| Q4 24 | — | $2.4M | ||
| Q3 24 | $14.1M | $3.9M | ||
| Q2 24 | — | $4.1M | ||
| Q1 24 | — | $5.4M |
总债务CBLLIRIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.0M | ||
| Q3 24 | — | $1.4M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CBLLIRIX
| Q4 25 | $155.3M | — | ||
| Q3 25 | $164.1M | $4.7M | ||
| Q2 25 | $172.2M | $6.1M | ||
| Q1 25 | $180.9M | $852.0K | ||
| Q4 24 | — | $2.1M | ||
| Q3 24 | $-136.0M | $2.6M | ||
| Q2 24 | — | $4.2M | ||
| Q1 24 | — | $6.5M |
总资产CBLLIRIX
| Q4 25 | $195.8M | $29.2M | ||
| Q3 25 | $199.5M | $28.4M | ||
| Q2 25 | $207.7M | $31.6M | ||
| Q1 25 | $213.5M | $34.2M | ||
| Q4 24 | — | $29.1M | ||
| Q3 24 | $47.1M | $30.2M | ||
| Q2 24 | — | $31.2M | ||
| Q1 24 | — | $34.1M |
负债/权益比CBLLIRIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.48× | ||
| Q3 24 | — | 0.53× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-10.8M | — |
| 自由现金流经营现金流 - 资本支出 | $-11.0M | — |
| 自由现金流率自由现金流/营收 | -44.2% | — |
| 资本支出强度资本支出/营收 | 0.7% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-41.6M | — |
8季度趋势，按日历期对齐
经营现金流CBLLIRIX
| Q4 25 | $-10.8M | — | ||
| Q3 25 | $-11.1M | $-1.2M | ||
| Q2 25 | $-7.5M | $-397.0K | ||
| Q1 25 | $-11.4M | $-1.1M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | — | $-3.1M | ||
| Q2 24 | — | $-1.3M | ||
| Q1 24 | — | $-1.6M |
自由现金流CBLLIRIX
| Q4 25 | $-11.0M | — | ||
| Q3 25 | $-11.5M | $-1.2M | ||
| Q2 25 | $-7.6M | $-410.0K | ||
| Q1 25 | $-11.6M | $-1.2M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | — | $-3.1M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-1.7M |
自由现金流率CBLLIRIX
| Q4 25 | -44.2% | — | ||
| Q3 25 | -50.8% | -9.4% | ||
| Q2 25 | -35.9% | -3.0% | ||
| Q1 25 | -56.4% | -9.8% | ||
| Q4 24 | — | -9.8% | ||
| Q3 24 | — | -26.5% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -14.0% |
资本支出强度CBLLIRIX
| Q4 25 | 0.7% | — | ||
| Q3 25 | 1.6% | 0.1% | ||
| Q2 25 | 0.3% | 0.1% | ||
| Q1 25 | 0.7% | 0.1% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CBLL
| Products | $18.8M | 76% |
| Subscription | $6.0M | 24% |
IRIX
暂无分部数据
